$CAMX (+2,09 %)

Here, too, I remain invested. @Multibagger

The obesity market continues to be one of the hottest areas in the biopharma sector - not least due to the bidding war between Pfizer and Novo Nordisk for Metsera. Recently, the focus of development has shifted to other parameters in addition to absolute weight reduction over a certain period of time. The Swedish company Camurus could contribute to this.

The company, which has its roots in the Swedish University of Lund, has its innovative FluidCrystal technology. The Scandinavians have designed the platform's approach for a long-lasting release of active ingredients. This enables effective treatment over longer periods of time with a single injection.

Camurus has now demonstrated this potential with the administration of semaglutide (Novo Nordisk's active ingredient contained in Ozempic and Wegovy). The substance CAM2056 was designed in such a way that in the long term only one monthly administration of semaglutide is necessary. Otherwise, the much-cited "weight loss injection" must be administered weekly.

The study showed that semaglutide administered as two biweekly starting doses, followed by two monthly doses, was well tolerated until the highest starting dose was reached. Particularly exciting: the results of the phase 1b study show a weight reduction of 9.3 percent with CAM2056 compared to 5.2 percent with weekly semaglutide administered on day 85.

"We are very pleased with the Phase 1b data, which show that CAM2056 is well tolerated and produces a dose-dependent reduction in body weight and A1c that matches or exceeds that observed with weekly semaglutide," summarized Camurus CEO Fredrik Tiberg. "The study data suggest that CAM2056 enables rapid dose titration without compromising tolerability, while allowing convenient monthly dosing. Further evaluation of CAM2056 is planned in an upcoming Phase 2b study."

Conclusion

Camurus once again demonstrates the platform potential of its FluidCrystal technology. The Swedes are already working with Eli Lilly in this area, while Novo Nordisk is relying on the expertise of Danish company Ascendis Pharma. Irrespective of this, Camurus can help to extend dosing intervals and reduce the inconvenience of injections. In the opinion of the AKTIONÄR, the potential of the Swedes in this area is clearly underestimated. Courageous investors should buy (stop: 47 euros).

https://www.deraktionaer.de/artikel/pharma-biotech/aktionaer-tipp-camurus-gamechanger-im-adipositas-markt-kurssprung-20390010.html

$CAMX (+2,09 %) I will remain invested here as well.

Oczyesa is now available for patients with acromegaly in Germany.

First once-monthly, subcutaneous octreotide treatment

Developed for self-administration and effective disease control

Lund, Sweden - November 3, 2025 - Camurus (NASDAQ STO: CAMX) today announced the launch of Oczyesa in Germany, the first country in the EU to do so. Oczyesa® , an octreotide depot preparation for subcutaneous administration, is approved for maintenance treatment in adults with acromegaly who have responded to and tolerated treatment with somatostatin analogs.¹

"We are pleased to announce that Oczyesa is now available for patients with acromegaly following marketing authorization by the European Commission," said Fredrik Tiberg, President and CEO and CSO of Camurus. "The drug enables sustained disease control and can be self-administered using an auto-injector. This improves the patient's quality of life and satisfaction with the treatment. Oczyesa will initially be launched in Germany; the market launch in other EU countries is planned."

An estimated 70,000 people in the EU live with acromegaly.

"There remains a significant unmet medical need for patients with acromegaly. They are often faced with a high treatment burden and a reduced quality of life," says Prof. Günter Stalla, Head of Medicover Neuroendocrinology in Munich. "Oczyesa offers a welcome new alternative that combines effective disease control with easy self-administration. This empowers patients and helps to optimize health resources."

Full article at the link ⬇️

https://news.cision.com/camurus-ab/r/camurus-launches-long-acting-oczyesa--for-the-treatment-of-acromegaly,c4260001

Hello my dears,

At the end of the month there was another rebalancing at "Tenbagger Holding".

The two companies that will be taken over next year have now been sold at a profit.

$IVG (+0,03 %) Iveco and $AWE (+0,47 %) Alphawave.

I have noticed that there has been hardly any movement in the share price for weeks. And that's why I want to use the capital for new investments at the end of the year.

One new addition already took place yesterday.

Once again, we are going to the USA, with one foot in the future-oriented sector of "quantum technology". Through the investment in $FEIM (-4,98 %) Frequency Electronics Inc.

Many will now be thinking "Why buy at an all-time high? For me, an ATH is a sign of strength. And in the past, I have often not found the entry point for such shares by waiting. For me, Frequency is a long-term investment, and with quantum technology we are only at the beginning.

If there is another correction, I will buy more.

There was also an additional purchase in $CAMX (+2,09 %) Camurus. I see pent-up demand in the pharmaceutical sector. And anyone who knows me knows that I go for the small but mighty.

Ladies and gentlemen, what do you think of the sale of the two takeover candidates?

Was it perhaps a mistake and should I have waited a little longer? Should I have waited for the price to improve? Or was it right to redeploy the capital at the end of the year?

By the way $IRBT (-5,69 %) iRobot in terms of the takeover. When the company was to be taken over by Amazon, the EU did not give its approval at the end. And the gamble ended up in a dead stock.

What do you think of my investment in Frequency Electronics? @EpsEra

I look forward to many comments.

Frequency Electronics, Inc. (FEI) was founded in 1961 and is a public company headquartered in Long Island, New York. FEI is traded on the NASDAQ Stock Exchange under the symbol FEIM. The Geschäftsführung of the company is managed by Dr. Thomas McClelland managed by

FEI and its subsidiaries are major global providers of precision time and frequency (PT&F) products for ground, sea, air and space terminals and platforms used by commercial and government/military system suppliers. For more information on our Fähigkeiten finden Sie unter diesem Link.

The company has four wholly owned subsidiaries Tochtergesellschaften. FEI Communications Inc. and FEI Government Systems Inc. are located in Mitchel Field, New York; FEI-Zyfer Inc. based in Garden Grove, California; and FEI-Elcom Tech Inc. headquartered in Northvale, New Jersey.

The company looks back on eine lange Geschichte and has evolved from a defense contract manufacturer to a high-tech provider of precision timing and frequency products used to synchronize voice, data and video transmissions in wireless communications systems. More Informationen zum Werden eines Anbieters finden Sie unter diesem Link.

FEI and its subsidiaries support the United States government with custom time and frequency solutions and products for defense and space applications.

Über uns - Frequency Electronics

$CAMX (+2,09 %) My dears, perhaps this little dip is a good opportunity. I remain invested.

Camurus fights the US drug crisis with innovative medicines

Camurus is at the forefront of the fight against the drug crisis in the US, which is characterized by the alarming rise in overdoses from synthetic opioids such as fentanyl. With its advanced FluidCrystal® technology, Camurus enables long-lasting drug release, which increases treatment efficacy and improves patient compliance. Studies show that Buvidal blocks the subjective effects of opioids from the very first dose and reduces the desire for further opioids.

Federal Minister of the Interior Alexander Dobrindt: "The drug business is the most dangerous field of organized crime. The numbers of cocaine and synthetic drugs are rising dramatically. Our investigators come across laboratories that produce tons of drugs in just a few weeks. And the smugglers are adapting: New routes, new methods, new brutality. This is not a marginal problem, it is a threat to our children, our society and our rule of law. We will tackle this with all our might - with stricter laws, tougher controls and consistent access to the criminals' money.

https://www.presseportal.de/blaulicht/pm/7/6144353

Hello my dears,

September is over.

That's why I'd like to give you a little overview of the month.

Tops: 📉

$INOD (-5,02 %)
$APP (-4,51 %)
$MU (-1,84 %)
$GILT (-3,45 %)
$PNG (-6,49 %)
$AVAV (-4,76 %)
$ASML (-1,27 %)

Flops: 📈

$UFPT (+0,88 %)
$CAMX (+2,09 %)
$TDG (+2,95 %)
$CMG (+0,82 %)
$TTEK (+14,65 %)
$CPRT (+0,34 %)
$CSU (-2,54 %)

It was noticeable in September that there were a lot of long runners and compounders among the flops. For this reason, I am relaxed for the time being and will stick to the values.

📉

My overall portfolio closed the month up 8.64 %.

$EQQQ (-1,5 %) NASDAQ 100. +4.81 %

$IWDA (-1,07 %) MSCI World. +2,62 %

$CAMX (+2,09 %)

Hello folks,

I remain invested. Perhaps this is a good time for interested parties to get in.

You can find information about the company in my post under the share.

https://getqu.in/dnwES6/

https://getqu.in/dnwES6/

In the long term, the takeover would strengthen the company's position in the market. And synergies and efficiency. I see cost savings through the pooling of resources, expertise and optimized processes.

The Swedish biotechnology company Camurus is reportedly in talks to acquire its US partner Braeburn Pharma. The deal would give the company full control of its opioid use disorder (OUD) product.

Several media outlets have reported that Lund-based Camurus is interested in regaining the rights to Brixadi (buprenorphine) in the large US market, more than a decade after it licensed the product to Braeburn there.

Brixadi is an extended-release subcutaneous injection - suitable for weekly and monthly use - that was approved by the FDA in 2023 for the treatment of moderate to severe OUD in patients already being treated with an oral (transmucosal) buprenorphine-containing product.

Since then, the product has made headway in the US - a large market for OUD therapies, as tens of thousands of lives continue to be lost each year due to an epidemic of opioid abuse there - and has put pressure on competing drugs.

That includes Indivior's Sublocade, which last year failed to reach its goal of $1 billion in annual sales for the drug as Brixadi gained momentum.

Camurus - which sells the drug in other markets under the name Buvidal - reported that Brixadi would take 25% of the long-acting buprenorphine segment by the end of 2024 and generate sales of SEK954 million ($103 million) outside the US in the first six months of this year, an increase of 28%.

While privately held Braeburn does not release financial results to provide insight into US sales, Camurus said its royalties on the drug had doubled to around $17.5 million in the first half of the year. The acquisition of Braeburn would allow Camurus to realize the full sales potential of the product. Some analysts believe that sales could exceed the one billion dollar mark per year.

Indivior announced in July that Sublocade had grown by 9% to 209 million US dollars after a decline in sales in the first quarter. The company raised its forecast for the full year to between 765 and 785 million US dollars. The company has reduced staff and cut costs in order to provide resources for the development of the Sublocade business in the USA.

Neither Camurus nor Braeburn commented on the acquisition rumors, and the speculation did not include an estimate of the financial nature of the deal, assuming it goes through.

https://moderndiplomacy.eu/2025/09/12/big-pharma-deal-swedish-camurus-to-acquire-us-braeburn/

https://pharmaphorum.com/news/rumour-mill-has-camurus-buying-partner-braeburn

$CAMX (+2,09 %)

Hello my dears,

I have just invested and am sticking with it.

Lund, Sweden - August 28, 2025 - Camurus (NASDAQ STO: CAMX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Oczyesa ®, a subcutaneous octreotide depot, for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.1

" Oczyesa, the first subcutaneous octreotide treatment for monthly administration, has demonstrated effective and sustained control of acromegaly and can be self-administered by patients using an auto-injection pen, " says Fredrik Tiberg, President & CEO, CSO at Camurus. " Camurus plans to launch the treatment in the UK in the fourth quarter of 2025. "

The MHRA's marketing authorization of Oczyesa is based on the results of a comprehensive clinical program comprising seven clinical trials, including two Phase 3 trials under the ACROINNOVA program.

Oczyesa is manufactured using Camurus' proprietary FluidCrystal® technology. The product is designed for convenient subcutaneous self-administration once monthly using a pre-filled autoinjector pen with a concealed thin needle.

Oczyesa received marketing authorization in the EU from the European Commission on June 30, 2025.

Information about acromegaly can be found at the link ⬇️

https://www.camurus.com/media/press-releases/2025/camurus-announces-approval-of-oczyesa-for-the-treatment-of-acromegaly-in-the-uk/

Hello my dears,

Investors like to take the P/E ratio as the price of a share for profitable shares.

P/E ratio: The P/E ratio, the price/earnings ratio, is a profitability ratio that is calculated as part of the stock analysis. The P/E ratio expresses the multiple of the annual profit at which a share is valued on the stock exchange.

Alternatively, the KCV is also used

KCV: The KCV (price/cash flow ratio) describes the relationship between the price of a share and the cash flow per share. The share price is divided by the cash flow per share. The interpretation is comparable to that of a P/E ratio (price/earnings ratio).

Using the example of my last purchase $CAMX (+2,09 %) Camurus

we can clearly see how the price (P/E ratio) will/has been reduced by 2027.

From 78.32 last year to the current 47.03

(Since the stock market almost always prices in the future, I am using the 3-year performance here, which was 203%).

This shows how well the price reduction is reflected in the performance (demand).

As in the supermarket, a price reduction also increases demand. Unless the product is not convincing, has expired or has other weaknesses.

In contrast to the supermarket, however, we have the advantage on the stock exchange that price reductions / price increases are more transparent over the next few years.

The difference on the stock market, however, is that we buy the product well before the price reduction. This is because we are making a bet on rising prices. Assuming that the price reduction will have an impact on performance.

(As we have seen in the example of Camurus).

We leave the product where the price will rise over the next few years on the shelf.

As the price (P/E ratio) of Camurus will be reduced to 16.05 by 2027, I bought the product. On the assumption that the price cuts will have an impact on demand (performance/price).

However, additional price reductions can always occur. This happens due to events such as: bad quarterly figures, bad news, 🍊 etc.

Such special offers are often an opportunity to buy more.

As a rule, falling prices (P/E ratios) are caused by rising profits. And rising prices logically come from falling profits.

This is one reason why I mainly invest in growth stocks.

That sounds as if the stock market is actually quite simple. And growth stocks are a guarantee for rising prices.

But it's not quite that simple.

Because the 🐻blues are on every corner.

My dears,

I look forward to your feedback and additions.

Have I forgotten anything?

@EpsEra

Hello my dears,

the love @yngfinn has asked me how I find shares. I would like to share my answer with you.

@yngfinn

Hello my dear,

as I have enough positions in my portfolio at the moment, I am no longer looking so intensively for new companies. I don't trade and am more long-term oriented.

My approach is quite different.

By sector:

I often look at which sectors and areas are currently on the move. Or what the areas of the future are, such as robotics, defense and aerospace, AI, etc.

But I also look at which sectors and countries in my portfolio are undervalued.

Or also in which sectors I see a need to catch up because they have been driven down unjustifiably. Like the healthcare sector, for example 🍊.

I watch reports and documentaries. Like exploring the oceans and seas. And discovering Kraken Robotic $PNG (-6,49 %) and Norbit $NORBT (-4,02 %) .

https://getqu.in/Ey45a0/

After Powel's speech on Friday, for example, it would now make sense to look for real estate and homebuilders. Like Buffet did with his stock Dr. Horten $DHI (-0,75 %) .

Unfortunately, the ongoing wars show the importance of drones and drone defense.

But also the increasing importance in agriculture (I have already written a post about this).

https://getqu.in/SdXvMm/

In the end, my choice here was $AVAV (-4,76 %) AeroVironment. And the contract manufacturer $KIT (+0,04 %) Kitron.

In the future-oriented robotics sector, I don't really want to invest in overvalued stocks such as $TSLA (-5,35 %) Tesla or the contract manufacturer $JBL (-5,1 %) Jabil. I see Japan as very innovative here. As shown by $7012 (-1,55 %) Kawasaki shows. This is how I discovered the blade supplier $6481 (+0,45 %) THK (there was a post from me about this).

https://getqu.in/fZudqX/

By country:

When Iran attacked Israel, I took advantage of the dip and picked Israeli stocks.

For example, I discovered Gilat $GILT (-3,45 %) for example.

But as a long-term investor, I still see the USA in the lead. I also like to take a look at small and mid caps.

But I also often look at countries that are not quite so much in focus. Scandinavia or Italy.

I have found $LTMC (+0,24 %) Lottomatica and $CAMX (+2,09 %) Camurus.

I often only look at the companies by momentum from the various indices in these countries.

By company:

I also often look at which companies are currently the stars on the stock market. Like Rheinmetall, for example, but then I don't go into the overvalued shares, but look for suppliers, i.e. blade suppliers. That's how I came across Kitron $KIT (+0,04 %) for example. Kitron as a contract manufacturer for the defense sector.

Or when Novo Nordisk was still a star, I discovered the Novo supplier $YPSN (-1,98 %) discovered.

Nvidia supplier $HY9H (-2,19 %) sk Hynix.

Where is the capex of the companies going?

Based on this question, I came across the AI infrastructure companies $IESC (-7,98 %) IES Holding and $VRT (-5,29 %) Vertiv.

The weakness of one company makes other companies strong.

The weakness of Boeing makes $AIR (-1,01 %) and $ERJ (-1,09 %) strong. That's how I came across Embraer and $MTX (+0,11 %) MTU.

https://getqu.in/4hiSbt/

Research and reports, such as on coinbase $COIN (-3,16 %) (CAUTION never buy based on a story).

https://getqu.in/OIiwhP/

Good company figures with a growth story could also be a reason. As for example with $GILD (+2,2 %) Gilead.

https://getqu.in/iF8BDY/

Takeover fantasies:

Takeover rumors usually mean that the share price of the company to be taken over rises.

As was the case with $AWE (+0,47 %) Alphawave was the case.

https://getqu.in/1NPNWI/

Or with Iveco $IVG (+0,03 %)

https://getqu.in/WJnLFp/

https://getqu.in/VnK4Xk/

CAUTION: Something can always go wrong here and send the share price plummeting.

I experienced this myself with i robot when the UK did not agree to a takeover by Amazon.

No matter in which area. My approach is usually to pick out the momentum stocks. I then look at the multiples, news, order situation and, of course, the company.

Compounders and long-term runners:

In my core, I only invest in quality stocks with a moat.

Here it makes sense not to buy at the ATH, but on the dip.

Multiples:

What is important to me with multiples:

-profitable company, or in the next year

Profitable.

Preferably double-digit profit growth with a falling P/E ratio.

-Percentage profit growth is higher than sales growth.

-good and rising EbiT margin.

-PEG below or around 1

-increasing free cash flow taking into account capex.

My dears,

I hope my brief summary of my approach perhaps offers you a little added value.

Please let me know in the comments.

Suggestions for improvement are also welcome. 😘😘

$CAMX (+2,09 %)

Hello my dears,

Camurus has just arrived.

I was thrilled to see that profits have doubled. And that the already good EbiT margin can be increased by a further 10%. As a result, the P/E ratio has halved and the PEG is a good 0.50.

Today's breakout from the prolonged sideways movement has encouraged me to buy.

https://aktie.traderfox.com/visualizations/SE0007692850/EI/camurus-ab

What does Camurus do?

Camurus is a biopharmaceutical company based in Sweden. The company specializes in the development and marketing of pharmaceuticals based on proprietary formulation technologies.

Camurus focuses on the treatment of chronic diseases and addictions. The company's approach is to develop longer-acting drug formulations in order to improve patient compliance and reduce the number of doses.

Camurus offers a range of products in various therapeutic areas, including pain management, oncology and endocrinology. The company strives to provide solutions that improve patients' quality of life and optimize clinical outcomes.

On June 3, 2025, the Swedish biopharmaceutical company Camurus and the US pharmaceutical group Eli Lilly announced a comprehensive collaboration and license agreement. The aim of this partnership is the development and global commercialization of long-acting incretin therapeutics.

Camurus Q2 2025: Record sales and profit with expansion of the product portfolio/s

https://de.investing.com/news/company-news/camurus-q2-2025-rekordumsatz-und-gewinn-bei-erweiterung-des-produktportfoliosn-93CH-3070249